Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma

Background. Endometrial stromal sarcomas (ESS) are a subtype of gynaecological sarcomas characterized by the overexpression of hormone receptors. Hormone treatment is widely used in ESS but primary or acquired resistance is common. The mammalian target of rapamycin (mTOR) pathway has been suggested...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Liberal, J., Benson, C., Messiou, C., Fisher, C., Judson, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109292/
https://www.ncbi.nlm.nih.gov/pubmed/25104960
http://dx.doi.org/10.1155/2014/612496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109292/
https://www.ncbi.nlm.nih.gov/pubmed/25104960
http://dx.doi.org/10.1155/2014/612496

Ejemplares similares